Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization

References

• Golan A, Ron-EL R, Herman A, Sofer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Survey. 1989;44:430–40.
   PubMedGoogle Scholar
• Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril. 1978;30:255–68.
   PubMed Web of Science ®Google Scholar
• Rizk B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod. 1991;6:1082–7.
   PubMed Web of Science ®Google Scholar
• Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 1999;71:808–14.
   PubMed Web of Science ®Google Scholar
• Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995;27:344–6.
   PubMed Web of Science ®Google Scholar
• Beerendonk CC, van Dop PA, Braat DD, Merkus JM. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Gynecol Surv. 1998;53:439–49.
   PubMedGoogle Scholar
• Fineschi V, Neri M, Di Donato S, Pomara C, Riezzo I, Turillazzi E. An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. Internat J Legal Med. 2006;120:293–9.
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559–77.
   PubMed Web of Science ®Google Scholar
• Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol. 2007;5:9.
   PubMed Web of Science ®Google Scholar
• Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249–61.
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, . Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112–20.
   PubMed Web of Science ®Google Scholar
• Macklon NS, Fauser BC. Follicle-stimulating hormone and advanced follicle development in the human. Arch Med Res. 2001;32:595–600.
   PubMed Web of Science ®Google Scholar
• Macklon N, Fauser BC. Regulation of follicle development and novel approaches to ovarian stimulation for IVF. Hum Reprod Update. 2000;6:307–12.
   PubMed Web of Science ®Google Scholar
• Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 1988;159:210–5.
   PubMed Web of Science ®Google Scholar
• Delvigne A, Dubois M, Battheu B, Bassil S, Meuleman C, De Sutter P, . The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod. 1993;8:1361–6.
   PubMed Web of Science ®Google Scholar
• Meirow D, Schenker JG, Rosler A. Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17 alpha-hydroxylase, 17,20-lyase deficiency: what is the role of oestrogens? Hum Reprod. 1996;11:2119–21.
   PubMed Web of Science ®Google Scholar
• Papanikolau EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, . Early and late ovarian hyperstimulation syndrome:early pregnancy outcome and profile. Hum Reprod. 2005;20:636–41.
   PubMed Web of Science ®Google Scholar
• Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update. 2003;9:275–89.
   PubMed Web of Science ®Google Scholar
• D'Angelo A, Amso N. “Coasting” (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane database Syst Rev (Online). 2002:CD002811.
   PubMedGoogle Scholar
• D'Angelo A, Amso N. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome. Cochrane database Syst Rev (Online). 2002:CD002806.
   PubMedGoogle Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane database Syst Rev (Online). 2006;3:CD001750.
   Google Scholar
• Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and a meta-analysis. Hum Reprod Update. 2006;12:651–71.
   PubMed Web of Science ®Google Scholar
• Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004;81:1–5.
   PubMed Web of Science ®Google Scholar
• Fauser BC, De Jong D, Oliviennes F, Wramsby H, Tay C, Itskowitz-Eldor J, . Endocrine profiles after triggering of final maturation with GnRH agonist after cotreatment with the GnRH antagonist ganerelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Matab. 2002;87:709–15.
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, . A lower ongoing pregnancy rate can be expected when GnrH agonist is used for triggering final oocyte maturation instead of hCG, in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887–92.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Gröndahl ML, Westergaard L, . GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213–20.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GNRH antagonist ovarian hyperstimulation protocol: a systematic review and a meta-analysis. Hum Reprod Update. 2006;12:159–168.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bredkjaer HE, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2009. (Epub Feb 5, 2009) (in press).
   Google Scholar
• Heijnen EM, Eijkemans MJ, De Klerk C, Polinder S, Beckers NG, Klinkert ER, . A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet. 2007;369:743–9.
   PubMed Web of Science ®Google Scholar
• Karlstrom PO, Bergh C. Reducing the number of embryos transferred in Sweden-impact on delivery and multiple birth rates. Hum Reprod. 2007;22:2202–7.
   PubMed Web of Science ®Google Scholar